10X Genomics Inc TXG

$90.04 +1.54 (1.74%)

Valuation

Market cap
11,530,754,000
Revenue TTM
$642,820,000
Net income TTM
$-43,540,000
PE ratio
0.00
Forward PE
—
Profit margin
-6.77%
Debt to equity
0.00

Trading

Volume
3,453,300
Avg volume
2,993,108
Day's range
$87.29 – $91.99
Shares out
130,291,000
Stochastic %K
89%
Beta
2.08
Analysts
Sell
Price target
$58.59

Price

Company profile

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromiu...

Show more

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Industry
Medical Devices
Sector
Healthcare
Phone
925 401 7300
Website
https://www.10xgenomics.com
Address
6230 Stoneridge Mall Road, Pleasanton, United States

Latest news

Stocktwits

Saber09 Sep 29, 3:55 PM 1 replies
ArmLee Sep 29, 2:17 PM
$RXRX This stock reminds me of all the pain I went through with $TXG I accumulated about 3000 shares at an average of $8.00, and it never looked back. Absolute MONSTER!!
0 replies
LockStocked Sep 29, 1:43 PM
$TXG Absolute monster
0 replies
flychicken1991 Sep 29, 1:07 PM
$TXG 10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions. Impact: Positive (76%). could receive modest upward valuation pressure from prospective paid software revenue and greater use of its spatial instruments and consumables. Free Early Access provides no demonstrated immediate Sentira revenue uplift... Source and what to watch next: https://nimpact.tech/newsimpact/news/5e3f16229e4fd1b0/txg-10x-genomics-announces-sentira-a-new-computational-platform-to-turn?utm_source=stocktwits&utm_medium=story_url
0 replies
Yingtrader7 Sep 29, 12:34 PM
$NSYS take a look at $TXG chart for a real winner.🤪
0 replies
Walakulu2000 Sep 28, 10:32 PM
$TXG $SPY TXG keeps going up for months.. 140% winner so far for me
0 replies
anachartanalyst Sep 28, 7:02 PM
$TXG https://anachart.com/wp-content/uploads/2026/09/1790622108_soc-img.jpg
0 replies
healthcareguru Sep 28, 6:08 PM
$TXG this is going to end in tears…there’s a reason every single insider is dumping stock reentless. INSANELY OVERVALUED bs reality. Would be a buyer <$50. 👎🐺 $XBI $XLV $IWM
3 replies